outbrain
Close  

China’s biggest pharma firm invites PH to join COVID-19 vaccine trial

By: - Reporter / @KHallareINQ
/ 10:11 PM May 20, 2020

MANILA, Philippines — China’s biggest pharmaceutical company, the state-owned Sinopharm, has invited the Philippines to join its trial of a vaccine for the coronavirus disease (COVID-19), Health Secretary Francisco Duque III bared Wednesday at the Senate Committee of the Whole hearing.

“We have a letter from China, from Sinopharm, China’s biggest pharmaceutical company, which offered to include us in its global clinical trial for their newly-developed vaccine,” Duque said.

ADVERTISEMENT

Previously, Sinopharm also extended a similar invitation to Pakistan.

In the Senate hearing, Duque also revealed that 148 patients had agreed to be part of the World Health Organization’s (WHO) Solidarity Trial for COVID-19 treatment.

FEATURED STORIES

As of Wednesday, the Philippines has 13,221 COVID-19 cases, of whom 842 have died while 2,932 have recovered.

/atm

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link .

Read Next
EDITORS' PICK
MOST READ
Don't miss out on the latest news and information.
View comments

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: China, coronavirus pandemic, coronavirus Philippines, COVID-19, Francisco Duque III, nCoV update, Sinopharm
For feedback, complaints, or inquiries, contact us.


© Copyright 1997-2020 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.